%0 Journal Article
%A Argüelles Arias, Federico
%A Hinojosa Del Val, Joaquín
%A Vera Mendoza, Isabel
%T Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.
%D 2018
%@ 1130-0108
%U http://hdl.handle.net/10668/12230
%X In 2013, the European Medicines Agency (EMA) approved the biosimilar infliximab (CT-P13) for the full range of indications of the originator product, based on data from two trials conducted in rheumatoid arthritis and ankylosing spondylitis. The same year, our Society published a position statement that was later reviewed.
%~